1. Home
  2. PLBY vs SGMT Comparison

PLBY vs SGMT Comparison

Compare PLBY & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBY

PLBY Group Inc.

HOLD

Current Price

$1.18

Market Cap

204.4M

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.69

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBY
SGMT
Founded
1953
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
204.4M
169.4M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
PLBY
SGMT
Price
$1.18
$7.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$3.00
$26.13
AVG Volume (30 Days)
990.7K
1.2M
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
87.50
N/A
EPS
N/A
N/A
Revenue
$120,928,000.00
$2,000,000.00
Revenue This Year
$9.17
N/A
Revenue Next Year
$7.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.13
N/A
52 Week Low
$1.19
$4.50
52 Week High
$2.75
$11.41

Technical Indicators

Market Signals
Indicator
PLBY
SGMT
Relative Strength Index (RSI) 33.85 63.11
Support Level N/A $7.09
Resistance Level $1.94 $8.80
Average True Range (ATR) 0.09 0.41
MACD -0.02 0.11
Stochastic Oscillator 2.33 88.60

Price Performance

Historical Comparison
PLBY
SGMT

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: